Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current pharmaceutical design

• Publication date

  2012-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/138161212799859710PMID 22352752
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The physiology and pathology of inositide signaling in the nucleus

  2011cited by this paper
• Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

  2011cited by this paper
• Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence

  2011cited by this paper
• The Search for Better Prognostic Models in Myelodysplastic Syndromes

  2011cited by this paper
• Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes

  2011cited by this paper
• Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.

  2010cited by this paper
• Nuclear inositide signaling in myelodysplastic syndromes

  2010cited by this paper
• Targeting DNA methylation for epigenetic therapy.

  2010cited by this paper
• The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.

  2010cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology.

  2009cited by this paper
• Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.

  2009cited by this paper
• Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

  2009cited by this paper
• A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

  2009cited by this paper
• Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

  2009cited by this paper
• Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

  2009cited by this paper
• A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

  2008cited by this paper
• A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

  2008cited by this paper
• DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.

  2008cited by this paper
• Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

  2008cited by this paper
• Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes

  2008cited by this paper
• Multiple roles of phosphoinositide-specific phospholipase C isozymes.

  2008cited by this paper
• Nuclear phospholipase C beta1 and cellular differentiation.

  2008cited by this paper
• Current treatment options and strategies for myelodysplastic syndromes

  2008cited by this paper
• Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.

  2008cited by this paper
• Gene silencing by DNA methylation in haematological malignancies

  2007cited by this paper
• A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.

  2007cited by this paper
• Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

  2007cited by this paper
• The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.

  2007cited by this paper
• Myelodysplastic syndromes: the complexity of stem-cell diseases

  2007cited by this paper
• CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine

  2007cited by this paper
• Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

  2007cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias

  2006cited by this paper
• Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.

  2006cited by this paper
• The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia

  2006cited by this paper
• Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients

  2006cited by this paper
• Nuclear inositol lipid metabolism: More than just second messenger generation?

  2005cited by this paper
• Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

  2005cited by this paper
• Molecular mechanisms of myelodysplastic syndrome.

  2003cited by this paper
• Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.

  2002cited by this paper
• Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene of phosphoinositide-specific phospholipase C beta(1).

  2000cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• Nuclear localization and signalling activity of phosphoinositidase Cβ in Swiss 3T3 cells

  1992cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper

• Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia.

  2020cites this paper
• Recent advances in MDS mutation landscape: Splicing and signalling.

  2019cites this paper
• Nuclear translocation of PKC‐ α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs)

  2017cites this paper
• Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes

  2016cites this paper
• Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation.

  2016cites this paper
• Phosphoinositide-specific phospholipase C in health and disease

  2015cites this paper
• An increased expression of PI‐PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes

  2015cites this paper
• Nuclear PI-PLCβ1: an appraisal on targets and pathology.

  2014cites this paper
• The physiological roles of primary phospholipase C.

  2013cites this paper
• Stem cells and tissue regeneration.

  2012cites this paper
• Current World Literature Bibliography Genes and cell metabolism Cancer control and prevention : nutrition and epigenetics

  year unknowncites this paper